

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
November 27, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Syndax Pharmaceuticals, Inc.

File No. 333-208861 - CF#36857

Syndax Pharmaceuticals, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on January 4, 2016, as amended.

Based on representations by Syndax Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.33	through May 9, 2021
Exhibit 10.34	through May 9, 2021
Exhibit 10.39	through May 9, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary